MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Harrow Health Operating Income 2011-2026 | HROW
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Harrow Health
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30.5 M | 8.82 M | 431 K | 1.92 M | 1.61 M | 385 K | -4.8 M | -5.22 M | -12.2 M | -15.9 M | -14.8 M | -10.1 M | -7.69 M | -4.18 M | -939 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 30.5 M | -15.9 M | -2.14 M |
Quarterly Operating Income Harrow Health
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.7 M | 11.4 M | -11.2 M | - | 1.32 M | 1.53 M | -6.93 M | - | 1.74 M | 2.35 M | 1.21 M | - | -94 K | 1.69 M | 2.1 M | - | -3.72 M | 4.17 M | 2.92 M | - | 1.6 M | -3.21 M | -628 K | - | -4.4 M | -767 K | -556 K | - | -649 K | -624 K | -1.78 M | - | -2.76 M | -3.02 M | -4.23 M | - | -4.61 M | -4.01 M | -3.75 M | - | -3.53 M | -3.48 M | -3.12 M | - | -2.46 M | -2.6 M | -2.34 M | - | -2.09 M | -2.23 M | -1.47 M | - | -1.25 M | -1.12 M | -352 K | - | -66.5 K | -146 K | -414 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.7 M | -11.2 M | -819 K |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M |  USA |
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-15.3 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 1.1 | 2.84 % | $ 118 M |  Canada |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | - | - | $ 2.06 B |  France |
 |
China Pharma Holdings
CPHI
|
-4.59 M | $ 0.59 | 6.08 % | $ 10.3 M |  China |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 3.81 | -16.81 % | $ 53.6 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Evolus
EOLS
|
-32.7 M | $ 5.68 | 37.53 % | $ 366 M | USA |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.65 | 4.89 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Emergent BioSolutions
EBS
|
-726 M | $ 8.95 | 0.39 % | $ 458 M | USA |
 |
Assertio Holdings
ASRT
|
-244 M | $ 12.19 | 2.48 % | $ 866 M | USA |
 |
Bausch Health Companies
BHC
|
963 M | $ 5.67 | -0.87 % | $ 2.07 B | Canada |
 |
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-55.6 M | - | - | $ 193 M | Canada |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.4 | 2.19 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-1.28 M | $ 2.87 | 0.01 % | $ 378 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.55 | 1.21 % | $ 3.37 M | Canada |
 |
Perrigo Company plc
PRGO
|
-1.12 B | $ 11.71 | 2.81 % | $ 1.62 B | USA |
 |
ProPhase Labs
PRPH
|
23.6 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
-6.67 M | $ 0.91 | 1.03 % | $ 21.2 M | USA |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 22.92 | 3.69 % | $ 1.06 B | USA |
 |
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-104 M | $ 4.79 | 2.57 % | $ 144 M | USA |
 |
SCYNEXIS
SCYX
|
72.7 M | $ 0.76 | 1.22 % | $ 36.4 M | USA |
 |
Solid Biosciences
SLDB
|
-130 M | $ 6.14 | 3.02 % | $ 251 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 2.74 | -0.36 % | $ 3.4 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
TherapeuticsMD
TXMD
|
-8.52 M | $ 2.25 | 1.35 % | $ 23.5 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 7.33 | -0.48 % | $ 4.53 B | Canada |
 |
Veru
VERU
|
-36.9 M | $ 2.53 | 0.4 % | $ 341 M | USA |
 |
Viatris
VTRS
|
766 M | $ 14.74 | -1.04 % | $ 17.7 B | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35.3 M | - | - | $ 55.5 M | USA |
 |
cbdMD
YCBD
|
-3.32 M | $ 0.75 | -2.76 % | $ 3.23 M | USA |